A Phase 1 interventional study of Vorasidenib 40 mg Oral Tablet and Ciprofloxacin 500 mg Oral Tablet in Healthy Subjects, sponsored by Servier Bio-Innovation LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-14.
Sponsored by Servier Bio-Innovation LLC · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objectives of this study are:
Servier Bio-Innovation LLC is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
In the opinion of the investigator, the subject is not suitable for entry into the study.
Additional Exclusion Criteria for Substudy B:
The subject is at high risk for QT prolongation, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single oral dose of 1×40 mg vorasidenib tablet administered under fasted conditions or following a low-fat meal.
Drug: Vorasidenib 40 mg Oral Tablet
A single oral dose of 1×40 mg vorasidenib tablet administered following a low-fat meal or under fasted conditions.
Drug: Vorasidenib 40 mg Oral Tablet
Single oral dose of vorasidenib 2×10 mg tablets administered on Day 1.
Drug: Vorasidenib 10 mg Oral Tablet
Single oral dose of vorasidenib 2×10 mg tablets administered on Day 1 and twice daily (morning and evening) oral doses of ciprofloxacin 1×500 mg tablet on Days 1 through 14.
Drug: Ciprofloxacin 500 mg Oral Tablet · Drug: Vorasidenib 10 mg Oral Tablet
Single oral dose of 1×40 mg vorasidenib tablet administered : * under fasted conditions (all subjects will fast overnight for at least 10 hours prior to dosing and for at least 4 hours after dosing. * or following a low fat meal (approximatively 400 to 500 calories) (Substudy A)
Twice daily (morning and evening) oral doses of ciprofloxacin 1×500 mg tablet on Days 1 through 14 (Substudy B)
Single oral dose of vorasidenib 2×10 mg tablets administered on Day 1 (Substudy B)
Cmax of Vorasidenib (substudy A)
Maximum observed plasma concentration of vorasidenib in substudy A
Time frame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose
Tmax of Vorasidenib (substudy A)
Time to maximum observed plasma concentration of vorasidenib in substudy A
Time frame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose
AUC0-t of Vorasidenib (substudy A)
Area under the plasma concentration versus time curve (AUC) from time 0 to the last quantifiable concentration (AUC0-t) of vorasidenib in substudy A
Time frame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose
AUC0-inf of Vorasidenib (substudy A)
AUC from time 0 extrapolated to infinity (AUC0-inf) of vorasidenib in substudy A
Time frame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose
Cmax of Vorasidenib (substudy B)
Maximum observed plasma concentration of vorasidenib in substudy B
Time frame: Before dosing and at multiple time points up to 504 hours on Day 22 after administration of vorasidenib.
Tmax of Vorasidenib (substudy B)
Time to maximum observed plasma concentration of vorasidenib in substudy B
Time frame: Before dosing and at multiple time points up to 504 hours on Day 22 after administration of vorasidenib.
AUC0-t of Vorasidenib (substudy B)
Area under the plasma concentration versus time curve (AUC) from time 0 to the last quantifiable concentration (AUC0-t) of vorasidenib in substudy B
Time frame: Before dosing and at multiple time points up to 504 hours on Day 22 after administration of vorasidenib.
AUC0-inf of Vorasidenib (substudy B)
AUC from time 0 extrapolated to infinity (AUC0-inf) of vorasidenib in substudy B
Time frame: Before dosing and at multiple time points up to 504 hours on Day 22 after administration of vorasidenib.
T1/2 of Vorasidenib (Substudy A)
Half-life f vorasidenib in substudy A
Time frame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose
CL/F of Vorasidenib (Substudy A)
Apparent oral clearance of vorasidenib in substudy A
Time frame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose
Vz/F of Vorasidenib (Substudy A)
Apparent volume of distribution of vorasidenib in substudy A
Time frame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose
Cmax of AGI-69460 (Substudy A)
Maximum observed plasma concentration of AGI-69460 in substudy A
Time frame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose
Tmax of AGI-69460 (substudy A)
Time to maximum observed plasma concentration of AGI-69460 (substudy A)
Time frame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose
AUC0-t of AGI-69460 (substudy A)
Area under the plasma concentration versus time curve (AUC) from time 0 to the last quantifiable concentration (AUC0-t) of AGI-69460 (substudy A)
Time frame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose
AUC0-inf of AGI-69460 (substudy A)
AUC from time 0 extrapolated to infinity (AUC0-inf) of AGI-69460 (substudy A)
Time frame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose
T1/2 of vorasidenib (substudy B)
Half-life of vorasidenib in substudy B
Time frame: Before dosing and at multiple time points up to 504 hours on Day 22 after administration of vorasidenib.
CL/F of vorasidenib (substudy B)
Apparent oral clearance of vorasidenib in substudy B
Time frame: Before dosing and at multiple time points up to 504 hours on Day 22 after administration of vorasidenib.
Vz/f
Apparent volume of distribution of vorasidenib in substudy B
Time frame: Before dosing and at multiple time points up to 504 hours on Day 22 after administration of vorasidenib.
Cmax of AGI-69460 (substudy B)
Maximum observed plasma concentration of AGI-69460 in substudy B
Time frame: Before dosing and at multiple time points up to 504 hours on Day 22 after administration of vorasidenib.
Tmax of AGI-69460 (substudy B)
Time to maximum observed plasma concentration of AGI-69460 (substudy B)
Time frame: Before dosing and at multiple time points up to 504 hours on Day 22 after administration of vorasidenib.
AUC0-t of AGI-69460 (substudy B)
Area under the plasma concentration versus time curve (AUC) from time 0 to the last quantifiable concentration of AGI-69460 (substudy B)
Time frame: Before dosing and at multiple time points up to 504 hours on Day 22 after administration of vorasidenib.
AUC0-inf of AGI-69460 (substudy B)
AUC from time 0 extrapolated to infinity (AUC0-inf) of AGI-69460 (substudy B)
Time frame: Before dosing and at multiple time points up to 504 hours on Day 22 after administration of vorasidenib.
Cmax of ciprofloxacin (substudy B)
Maximum observed plasma concentration of ciprofloxacin in substudy B
Time frame: Before dosing on Day 18 and on multiple time points up to 12 h after dosing
Tmax of ciprofloxacin (substudy B)
Tmax of ciprofloxacine (substudy B)
Time frame: Before dosing on Day 18 and on multiple time points up to 12 h after dosing
AUC0-t of ciprofloxacin (substudy B)
Area under the plasma concentration versus time curve (AUC) from time 0 to the last quantifiable concentration of ciprofloxacin (substudy B)
Time frame: Before dosing on Day 18 and on multiple time points up to 12 h after dosing
AUC0-12 of ciprofloxacin (substudy B)
Area under the plasma concentration versus time curve (AUC) from time 0 to 12h of ciprofloxacin (substudy B)
Time frame: Before dosing on Day 18 and on multiple time points up to 12 h after dosing
Plan to share: Yes — Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data. Access can be requested for all interventional clinical studies: used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US). where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope. In addition, access can be requested for all interventional clinical studies in patients: sponsored by Servier with a first patient enrolled as of 1 January 2004 onwards for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: After Marketing Authorisation in EEA or US if the study is used for the approval
Access criteria: Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed
Data sharing details ↗ · clinicaltrials.servier.com
No publications or documents are linked to this record.
Ran from Apr 2023 to primary completion in Jul 2023, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vorasidenib · Ciprofloxacin
Servier Bio-Innovation LLC